Wu Xiaonan, Zhao Jun, Yang Ling, Nie Xin, Wang Zheng, Zhang Ping, Li Chao, Hu Xueqing, Tang Min, Yi Yuting, Du Xinhua, Xia Xuefeng, Guan Yanfang, Yu Zicheng, Gu Wenguang, Quan Xiangming, Li Lin, Shi Hong
Department of Medical Oncology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Department of Thoracic Medical Oncology, Peking University, School of Oncology, Beijing Cancer Hospital & Institute, Beijing, P. R. China.
J Cancer. 2022 Mar 6;13(5):1565-1572. doi: 10.7150/jca.65370. eCollection 2022.
: More than 40% of lung cancer patients are diagnosed at ages over 70. However, the genomic and clinical characteristics among them remain elusive. Here, we performed targeted capture sequence to characterize the mutational spectrum of Chinese lung adenocarcinoma (LUAD) patients across ages. : 2025 LUAD patients were divided into three groups: young (≤50 years old) (n=416, 20.54%), intermediate (51~69 years old) (n=1271, 62.77%), and aged (≥70 years old) (n=338, 16.69%). 1,021-gene panel and 59-gene panel were used for sequencing with tissue samples. Genetic alterations and tumor mutation burden (TMB) in LUAD patients were investigated. : The frequency of mutations affecting 20 genes were significantly higher in aged group than in young group, and fourteen of them were not reported before, including involved in cell cycle/apoptosis signaling (), DNA damage repair ( and ), chromatin histone modification (), signaling ( and ), signaling ( and ) and other signaling pathway or cellular regulatory factor ( and ). Six previously reported mutated genes (, , , and ) were also significantly more frequent in aged group. Among clinical actionable mutation sites, mutation was presented more common in aged group; both exon 14 skipping and amplification were significantly positively correlated with old age; the fusions of , exon 20 insertion were less frequent in aged group. Furthermore, a higher level of TMB was found in aged group compared with young group. In this study, we revealed the differences of somatic genetic mutations and TMB between young and aged LUAD patients, which may provide directions of targeted therapy and advantages of immunotherapy for the elderly in the future.
超过40%的肺癌患者在70岁以上被诊断出来。然而,他们的基因组和临床特征仍然难以捉摸。在此,我们进行了靶向捕获测序,以表征不同年龄段中国肺腺癌(LUAD)患者的突变谱。2025例LUAD患者被分为三组:年轻组(≤50岁)(n = 416,20.54%)、中年组(51~69岁)(n = 1271,62.77%)和老年组(≥70岁)(n = 338,16.69%)。使用1021基因panel和59基因panel对组织样本进行测序。研究了LUAD患者的基因改变和肿瘤突变负荷(TMB)。老年组中影响20个基因的突变频率显著高于年轻组,其中14个基因以前未被报道,包括参与细胞周期/凋亡信号传导()、DNA损伤修复(和)、染色质组蛋白修饰()、信号传导(和)、信号传导(和)以及其他信号通路或细胞调节因子(和)。六个先前报道的突变基因(、、、和)在老年组中也明显更频繁。在临床可操作的突变位点中,突变在老年组中更常见;外显子14跳跃和扩增均与老年显著正相关;、外显子插入20的融合在老年组中较少见。此外,老年组的TMB水平高于年轻组。在本研究中,我们揭示了年轻和老年LUAD患者之间体细胞基因突变和TMB的差异,这可能为未来老年患者的靶向治疗方向和免疫治疗优势提供依据。